S529 Choosing Stool DNA vs Colonoscopy: Racial, Geographic, and Age Disparities in Colorectal Cancer Screening From BRFSS Data (2022–2023)

Introduction: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality in the United States. Despite the proven effectiveness of screening, significant disparities persist in modality uptake especially among racial/ethnic minorities, rural residents, and younger adults. This study examined sociodemographic predictors of choosing stool DNA testing over endoscopic methods (colonoscopy/sigmoidoscopy) using pooled Behavioral Risk Factor Surveillance System (BRFSS) 2022–2023 data. Methods: We analyzed adults aged 45–75 years who reported undergoing either stool DNA or endoscopic CRC screening. Bivariate associations were assessed using chi-square tests. Multivariable logistic regression evaluated predictors of stool DNA-only use, adjusting for sex, age, race/ethnicity, residence, and insurance. Results: Among 30,932 screening-eligible respondents, 2,780 (9.0%) used stool DNA testing exclusively. Women (AOR: 1.48; 95% CI: 1.37–1.60) and rural residents (AOR: 1.23; 95% CI: 1.10–1.38) had higher odds of stool DNA use. Asians (AOR: 1.55; 95% CI: 1.18–2.03) and Hispanics (AOR: 1.49; 95% CI: 1.28–1.73) were significantly more likely than Whites to use stool DNA. Use declined steeply with age, with adults ≥70 years having nearly 80% lower odds compared to those aged 45–49. Conclusion: Stool DNA testing is more frequently adopted among rural residents, Asians, Hispanics, and younger adults, groups historically underserved by endoscopy-based screening. These trends suggest that non-invasive stool-based modalities, such as Cologuard and FIT, may serve as vital tools for bridging colorectal cancer screening gaps across marginalized populations, especially given that endoscopy-based screening tends to favor urban, White, and older populations. Public health programs should prioritize expanding access to these tests to improve equity in CRC screening and reduce the long-standing disparities tied to geography, age, and race.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001129576.15709.dc
Primary Topic
Colorectal Cancer Screening and Detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S529 Choosing Stool DNA vs Colonoscopy: Racial, Geographic, and Age Disparities in Colorectal Cancer Screening From BRFSS Data (2022–2023)

Dennis Collins, Bahar Rehan, Mohammed Janajri, Yeshika Thapa et al.
The American Journal of Gastroenterology
Colorectal Cancer Screening and Detection
article

S529 Choosing Stool DNA vs Colonoscopy: Racial, Geographic, and Age Disparities in Colorectal Cancer Screening From BRFSS Data (2022–2023)

Dennis Collins, Bahar Rehan, Mohammed Janajri, Yeshika Thapa, Kobina Essilfie‐Quaye, Dennis Dela Tsagli
article en

Abstract

Introduction: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality in the United States. Despite the proven effectiveness of screening, significant disparities persist in modality uptake especially among racial/ethnic minorities, rural residents, and younger adults. This study examined sociodemographic predictors of choosing stool DNA testing over endoscopic methods (colonoscopy/sigmoidoscopy) using pooled Behavioral Risk Factor Surveillance System (BRFSS) 2022–2023 data. Methods: We analyzed adults aged 45–75 years who reported undergoing either stool DNA or endoscopic CRC screening. Bivariate associations were assessed using chi-square tests. Multivariable logistic regression evaluated predictors of stool DNA-only use, adjusting for sex, age, race/ethnicity, residence, and insurance. Results: Among 30,932 screening-eligible respondents, 2,780 (9.0%) used stool DNA testing exclusively. Women (AOR: 1.48; 95% CI: 1.37–1.60) and rural residents (AOR: 1.23; 95% CI: 1.10–1.38) had higher odds of stool DNA use. Asians (AOR: 1.55; 95% CI: 1.18–2.03) and Hispanics (AOR: 1.49; 95% CI: 1.28–1.73) were significantly more likely than Whites to use stool DNA. Use declined steeply with age, with adults ≥70 years having nearly 80% lower odds compared to those aged 45–49. Conclusion: Stool DNA testing is more frequently adopted among rural residents, Asians, Hispanics, and younger adults, groups historically underserved by endoscopy-based screening. These trends suggest that non-invasive stool-based modalities, such as Cologuard and FIT, may serve as vital tools for bridging colorectal cancer screening gaps across marginalized populations, especially given that endoscopy-based screening tends to favor urban, White, and older populations. Public health programs should prioritize expanding access to these tests to improve equity in CRC screening and reduce the long-standing disparities tied to geography, age, and race.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 58%
Colorectal Cancer Screening and Detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

S529 Choosing Stool DNA vs Colonoscopy: Racial, Geographic, and Age Disparities in Colorectal Cancer Screening From BRFSS Data (2022–2023) — Dennis Collins, Bahar Rehan, et al. · The American Journal of Gastroenterology (2025) | TGRS Research Map | TGRS